RT Journal Article SR Electronic T1 EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.05.21256010 DO 10.1101/2021.05.05.21256010 A1 Gautheron, Jérémie A1 Morisseau, Christophe A1 Chung, Wendy K. A1 Zammouri, Jamila A1 Auclair, Martine A1 Baujat, Geneviève A1 Capel, Emilie A1 Moulin, Célia A1 Wang, Yuxin A1 Yang, Jun A1 Hammock, Bruce D A1 Cerame, Barbara A1 Phan, Franck A1 Fève, Bruno A1 Vigouroux, Corinne A1 Andreelli, Fabrizio A1 Jéru, Isabelle YR 2021 UL http://medrxiv.org/content/early/2021/05/07/2021.05.05.21256010.abstract AB Epoxide hydrolases (EHs) regulate cellular homeostasis through hydrolysis of epoxides to less reactive diols. The first discovered EH was EPHX1, also known as mEH. EH functions remains partly unknown and no pathogenic variants have been reported in humans. We identified two de novo variants located in EPHX1 catalytic site in patients with a lipoatrophic diabetes characterized by loss of adipose tissue, insulin resistance, and multiple organ dysfunction. Functional analyses revealed that these variants led to the protein aggregation within the endoplasmic reticulum and to a loss of its hydrolysis activity. CRISPR-Cas9-mediated Ephx1 knockout (KO) abolished adipocyte differentiation and decreased insulin response. This KO also promoted oxidative stress and cellular senescence, an observation confirmed in patient-derived fibroblasts. A major beneficial effect of metreleptin therapy was observed. This translational study highlights the importance of epoxide regulation for adipocyte function, and provides new insights into the physiological roles of EHs in humans.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJeremie Gautheron is supported by grants from the Mairie de Paris (Emergences), the Societe Francophone du Diabete (SFD), the Institute of Cardiometabolism and Nutrition (ICAN), and the Fondation pour la Recherche Medicale (FRM grant numbers ARF20170938613 & EQU202003010517). Wendy K Chung received funding from the National Institutes of Health (NIH grant DK52431). Isabelle Jeru is supported by the FRM (EQU201903007868), AP-HP and Saint-Antoine Research Center. Christophe Morisseau is supported by a grant from the National Institute of Environmental Health Sciences (NIEHS; grant R35ES030443), and NIEHS Superfund Research Program (P42 ES004699).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained written informed consent for all genetic studies as well as for the use of photographs shown in Fig. 1. The study was approved by the CPP Ile de France 5 research ethics board (Paris, France) and the Columbia institutional review board (New York, United States).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlasmids used in this study have been deposited in Addgene under accession number 79368. Exome data from human subjects cannot been made freely and widely available.